LPA receptor signaling: Pharmacology, physiology, and pathophysiology

Journal of Lipid Research

Volumn 55, Issue 7, 2014, Pages 1192-1214

  Yung, Yun C ^a   Stoddard, Nicole C ^a,b   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Autotaxin; Brain lipids; Cancer; Fi brosis; Lysophosphatidic acid; Lysophospholipid; Obesity; Pain; Reproduction

Indexed keywords

ALPHA BROMOMETHYLENE BROMOMETHYLENE; AM 095; AM 152; ANTIDIABETIC AGENT; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINOCICEPTIVE AGENT; ANTIRHEUMATIC AGENT; AUTOTAXIN; DERMATOLOGICAL AGENT; KI 16425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID 1 ANTAGONIST; LYSOPHOSPHATIDIC ACID 1 RECEPTOR; LYSOPHOSPHATIDIC ACID 2 RECEPTOR; LYSOPHOSPHATIDIC ACID 3 RECEPTOR; LYSOPHOSPHATIDIC ACID 4 RECEPTOR; LYSOPHOSPHATIDIC ACID 5 RECEPTOR; LYSOPHOSPHATIDIC ACID 6 RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; SAR 100842; UNCLASSIFIED DRUG; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; LYSOPHOSPHOLIPID;

ARTHRITIS; ATHEROSCLEROSIS; AUTISM; AZOOSPERMIA; BONE DEVELOPMENT; BONE DISEASE; BREAST CANCER; CANCER CELL LINE; DEVELOPMENTAL STAGE; FEMALE GENITAL SYSTEM; FEMALE INFERTILITY; FIBROSING ALVEOLITIS; FIBROSIS; HEART INFARCTION; HUMAN; HYDROCEPHALUS; IMPAIRED GLUCOSE TOLERANCE; KIDNEY FIBROSIS; KNEE OSTEOARTHRITIS; LIVER FIBROSIS; MALE GENITAL SYSTEM; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHOSPHOLIPID METABOLISM; PHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; RETINA INJURY; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; ANIMAL; BIOLOGICAL MODEL; METABOLISM;

ANIMALS; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LYSOPHOSPHOLIPIDS; MODELS, BIOLOGICAL; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION;

EID: 84903283310     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R046458     Document Type: Review

References (346)

1. van Meer, G., D. R. Voelker, and G. W. Feigenson. 2008. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9: 112-124.
2. Vogt, W. 1963. Pharamacologically active acidic phospholipids and glycolipids. Biochem. Pharmacol. 12: 415-420.
3. Sen, S., R. R. Smeby, and F. M. Bumpus. 1968. Antihypertensive effect of an isolated phospholipid. Am. J. Physiol. 214: 337-341.
4. Tokumura, A., K. Fukuzawa, and H. Tsukatani. 1978. Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. Lipids. 13: 572-574.
5. Blankley, C. J., and H. R. Kaplan. 1984. Biologically active phospholipids as potential cardiovascular drugs. Drug Develop. Res. 4: 351-372.
6. Pörn, M. I., K. E. Akerman, and J. P. Slotte. 1991. High-density lipoproteins induce a rapid and transient release of Ca2+ in cultured fi broblasts. Biochem. J. 279: 29-33.
7. Gerrard, J. M., S. E. Kindom, D. A. Peterson, J. Peller, K. E. Krantz, and J. G. White. 1979. Lysophosphatidic acids. Infl uence on platelet aggregation and intracellular calcium fl ux. Am. J. Pathol. 96: 423-438.
8. Snyder, F. 1990. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am. J. Physiol. 259: C697-C708.
9. van Corven, E. J., A. Groenink, K. Jalink, T. Eichholtz, and W. H. Moolenaar. 1989. Lysophosphatidate-induced cell proliferation: identifi cation and dissection of signaling pathways mediated by G proteins. Cell. 59: 45-54.
10. Hecht, J. H., J. A. Weiner, S. R. Post, and J. Chun. 1996. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135: 1071-1083.
11. Chun, J., T. Hla, K. R. Lynch, S. Spiegel, and W. H. Moolenaar. 2010. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62: 579-587.
12. An, S., T. Bleu, W. Huang, O. G. Hallmark, S. R. Coughlin, and E. J. Goetzl. 1997. Identifi cation of cDNAs encoding two G proteincoupled receptors for lysosphingolipids. FEBS Lett. 417: 279-282.
13. An, S., T. Bleu, O. G. Hallmark, and E. J. Goetzl. 1998. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273: 7906-7910.
14. Bandoh, K., J. Aoki, H. Hosono, S. Kobayashi, T. Kobayashi, K. Murakami-Murofushi, M. Tsujimoto, H. Arai, and K. Inoue. 1999. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274: 27776-27785.
15. Fukushima, N., I. Ishii, J. J. Contos, J. A. Weiner, and J. Chun. 2001. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41: 507-534.
16. Lee, M. J., S. Thangada, C. H. Liu, B. D. Thompson, and T. Hla. 1998. Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J. Biol. Chem. 273: 22105-22112.
17. Devane, W. A., L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258: 1946-1949.
18. Sugiura, T., S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215: 89-97.
19. Noguchi, K., S. Ishii, and T. Shimizu. 2003. Identifi cation of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278: 25600-25606.
20. Kotarsky, K., A. Boketoft, J. Bristulf, N. E. Nilsson, A. Norberg, S. Hansson, C. Owman, R. Sillard, L. M. Leeb-Lundberg, and B. Olde. 2006. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 318: 619-628.
21. Lee, C. W., R. Rivera, S. Gardell, A. E. Dubin, and J. Chun. 2006. GPR92 as a new G12/13-and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281: 23589-23597.
22. Pasternack, S. M., I. von Kugelgen, K. A. Aboud, Y-A. Lee, F. Ruschendorf, K. Voss, A. M. Hillmer, G. J. Molderings, T. Franz, A. Ramirez, et al. 2008. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 40: 329-334.
23. Yanagida, K., K. Masago, H. Nakanishi, Y. Kihara, F. Hamano, Y. Tajima, R. Taguchi, T. Shimizu, and S. Ishii. 2009. Identifi cation and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J. Biol. Chem. 284: 17731-17741.
24. Makide, K., H. Kitamura, Y. Sato, M. Okutani, and J. Aoki. 2009. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat. 89: 135-139.
25. Kano, K., N. Arima, M. Ohgami, and J. Aoki. 2008. LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr. Med. Chem. 15: 2122-2131.
26. Aoki, J., A. Inoue, and S. Okudaira. 2008. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta. 1781: 513-518.
27. Bektas, M., S. G. Payne, H. Liu, S. Goparaju, S. Milstien, and S. Spiegel. 2005. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J. Cell Biol. 169: 801-811.
28. Pagès, C., M-F. Simon, P. Valet, and J. S. Saulnier-Blache. 2001. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat. 64: 1-10.
29. Okudaira, S., H. Yukiura, and J. Aoki. 2010. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie. 92: 698-706.
30. McIntyre, T. M., A. V. Pontsler, A. R. Silva, A. St Hilaire, Y. Xu, J. C. Hinshaw, G. A. Zimmerman, K. Hama, J. Aoki, H. Arai, et al. 2003. Identifi cation of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA. 100: 131-136.
31. Aoki, J. 2004. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 15: 477-489.
32. Sugiura, T., S. Nakane, S. Kishimoto, K. Waku, Y. Yoshioka, A. Tokumura, and D. J. Hanahan. 1999. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim. Biophys. Acta. 1440: 194-204.
33. Aoki, J., A. Taira, Y. Takanezawa, Y. Kishi, K. Hama, T. Kishimoto, K. Mizuno, K. Saku, R. Taguchi, and H. Arai. 2002. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J. Biol. Chem. 277: 48737-48744.
34. Hosogaya, S., Y. Yatomi, K. Nakamura, R. Ohkawa, S. Okubo, H. Yokota, M. Ohta, H. Yamazaki, T. Koike, and Y. Ozaki. 2008. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann. Clin. Biochem. 45: 364-368.
35. Watanabe, N., H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume, J. Aoki, K. Hama, S. Okudaira, M. Tanaka, T. Tomiya, et al. 2007. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J. Clin. Gastroenterol. 41: 616-623.
36. Sano, T., D. Baker, T. Virag, A. Wada, Y. Yatomi, T. Kobayashi, Y. Igarashi, and G. Tigyi. 2002. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem. 277: 21197-21206.
37. Yatomi, Y., K. Igarashi, K. Nakamura, R. Ohkawa, A. Masuda, A. Suzuki, T. Kishimoto, H. Ikeda, and J. Aoki. 2013. Clinical introduction of lysophosphatidic acid (LPA) and autotaxin assays. In Lysophospholipid Receptors Signaling and Biochemistry. J. Chun, T. Hla, W. H. Moolenaar, et al., editors. Wiley, Hoboken, NJ. 709-735.
38. Scherer, M., G. Schmitz, and G. Liebisch. 2009. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry. Clin. Chem. 55: 1218-1222.
39. Tokumura, A., K. Harada, K. Fukuzawa, and H. Tsukatani. 1986. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta. 875: 31-38.
40. Eichholtz, T., K. Jalink, I. Fahrenfort, and W. H. Moolenaar. 1993. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291: 677-680.
41. Tanaka, M., Y. Kishi, Y. Takanezawa, Y. Kakehi, J. Aoki, and H. Arai. 2004. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett. 571: 197-204.
42. Ma, L., H. Uchida, J. Nagai, M. Inoue, J. Aoki, and H. Ueda. 2010. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injuryinduced neuropathic pain. J. Pharmacol. Exp. Ther. 333: 540-546.
43. Yung, Y. C., T. Mutoh, M. E. Lin, K. Noguchi, R. R. Rivera, J. W. Choi, M. A. Kingsbury, and J. Chun. 2011. Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci. Transl. Med. 3: 99ra87.
44. Tokumura, A., S. Taira, M. Kikuchi, T. Tsutsumi, Y. Shimizu, and M. A. Watsky. 2012. Lysophospholipids and lysophospholipase D in rabbit aqueous humor following corneal injury. Prostaglandins Other Lipid Mediat. 97: 83-89.
45. Liliom, K., Z. Guan, J. L. Tseng, D. M. Desiderio, G. Tigyi, and M. A. Watsky. 1998. Growth factor-like phospholipids generated after corneal injury. Am. J. Physiol. 274: C1065-C1074.
46. Smyth, S. S., H-Y. Cheng, S. Miriyala, M. Panchatcharam, and A. J. Morris. 2008. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim. Biophys. Acta. 1781: 563-570.
47. Aaltonen, N., J. T. Laitinen, and M. Lehtonen. 2010. Quantifi cation of lysophosphatidic acids in rat brain tissue by liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878: 1145-1152.
48. Lee, J. W., S. Nishiumi, M. Yoshida, E. Fukusaki, and T. Bamba. 2013. Simultaneous profi ling of polar lipids by supercritical fl uid chromatography/tandem mass spectrometry with methylation. J. Chromatogr. A. 1279: 98-107.
49. Dohi, T., K. Miyauchi, R. Ohkawa, K. Nakamura, T. Kishimoto, T. Miyazaki, A. Nishino, N. Nakajima, K. Yaginuma, H. Tamura, et al. 2012. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin. Chim. Acta. 413: 207-212.
50. Ikeda, H., K. Enooku, R. Ohkawa, K. Koike, and Y. Yatomi. 2013. Plasma lysophosphatidic acid levels and hepatocellular carcinoma. Hepatology. 57: 417-418.
51. Brindley, D. N., and C. Pilquil. 2009. Lipid phosphate phosphatases and signaling. J. Lipid Res. 50(Suppl): S225-S230.
52. Saba, J. D. 2004. Lysophospholipids in development: miles apart and edging in. J. Cell. Biochem. 92: 967-992.
53. Kok, B. P., G. Venkatraman, D. Capatos, and D. N. Brindley. 2012. Unlike two peas in a pod: lipid phosphate phosphatases and phosphatidate phosphatases. Chem. Rev. 112: 5121-5146.
54. Bräuer, A. U., N. E. Savaskan, H. K̈hn, S. Prehn, O. Ninnemann, and R. Nitsch. 2003. A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat. Neurosci. 6: 572-578.
55. Stracke, M. L., H. C. Krutzsch, E. J. Unsworth, A. Arestad, V. Cioce, E. Schiffmann, and L. A. Liotta. 1992. Identifi cation, purifi cation, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267: 2524-2529.
56. Tokumura, A., E. Majima, Y. Kariya, K. Tominaga, K. Kogure, K. Yasuda, and K. Fukuzawa. 2002. Identifi cation of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277: 39436-39442.
57. Umezu-Goto, M., Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G. B. Mills, K. Inoue, J. Aoki, et al. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158: 227-233.
58. Lee, H. Y., T. Clair, P. T. Mulvaney, E. C. Woodhouse, S. Aznavoorian, L. A. Liotta, and M. L. Stracke. 1996. Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J. Biol. Chem. 271: 24408-24412.
59. Hama, K., J. Aoki, M. Fukaya, Y. Kishi, T. Sakai, R. Suzuki, H. Ohta, T. Yamori, M. Watanabe, J. Chun, et al. 2004. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and nonneoplastic cells through LPA1. J. Biol. Chem. 279: 17634-17639.
60. Bächner, D., M. Ahrens, N. Betat, D. Schröder, and G. Gross. 1999. Developmental expression analysis of murine autotaxin (ATX). Mech. Dev. 84: 121-125.
61. Lee, H. Y., J. Murata, T. Clair, M. H. Polymeropoulos, R. Torres, R. E. Manrow, L. A. Liotta, and M. L. Stracke. 1996. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem. Biophys. Res. Commun. 218: 714-719.
62. Savaskan, N. E., L. Rocha, M. R. Kotter, A. Baer, G. Lubec, L. A. van Meeteren, Y. Kishi, J. Aoki, W. H. Moolenaar, R. Nitsch, et al. 2007. Autotaxin (NPP-2) in the brain: cell type-specifi c expression and regulation during development and after neurotrauma. Cell. Mol. Life Sci. 64: 230-243.
63. Nakamura, K., R. Ohkawa, S. Okubo, H. Yokota, H. Ikeda, Y. Yatomi, K. Igarashi, K. Ide, T. Kishimoto, A. Masuda, et al. 2009. Autotaxin enzyme immunoassay in human cerebrospinal fl uid samples. Clin. Chim. Acta. 405: 160-162.
64. Nakasaki, T., T. Tanaka, S. Okudaira, M. Hirosawa, E. Umemoto, K. Otani, S. Jin, Z. Bai, H. Hayasaka, Y. Fukui, et al. 2008. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am. J. Pathol. 173: 1566-1576.
65. Kanda, H., R. Newton, R. Klein, Y. Morita, M. D. Gunn, and S. D. Rosen. 2008. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 9: 415-423.
66. Bai, Z., L. Cai, E. Umemoto, A. Takeda, K. Tohya, Y. Komai, P. T. Veeraveedu, E. Hata, Y. Sugiura, A. Kubo, et al. 2013. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J. Immunol. 190: 2036-2048.
67. Tanaka, M., S. Okudaira, Y. Kishi, R. Ohkawa, S. Iseki, M. Ota, S. Noji, Y. Yatomi, J. Aoki, and H. Arai. 2006. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281: 25822-25830.
68. van Meeteren, L. A., P. Ruurs, C. Stortelers, P. Bouwman, M. A. van Rooijen, J. P. Pradere, T. R. Pettit, M. J. Wakelam, J. S. Saulnier-Blache, C. L. Mummery, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26: 5015-5022.
69. Koike, S., K. Keino-Masu, and M. Masu. 2010. Defi ciency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway. Biochem. Biophys. Res. Commun. 400: 66-71.
70. Teo, S. T., Y. C. Yung, D. R. Herr, and J. Chun. 2009. Lysophosphatidic acid in vascular development and disease. IUBMB Life. 61: 791-799.
71. Chen, Y., D. P. Ramakrishnan, and B. Ren. 2013. Regulation of angiogenesis by phospholipid lysophosphatidic acid. Front. Biosci. (Landmark Ed). 18: 852-861.
72. Panetti, T. S., H. Chen, T. M. Misenheimer, S. B. Getzler, and D. F. Mosher. 1997. Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J. Lab. Clin. Med. 129: 208-216.
73. Lee, H., E. J. Goetzl, and S. An. 2000. Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am. J. Physiol. Cell Physiol. 278: C612-C618.
74. Lin, C. H., J. Lu, and H. Lee. 2011. Interleukin-1-Expression is required for lysophosphatidic acid-induced lymphangiogenesis in human umbilical vein endothelial cells. Int. J. Infl am. 2011: 351010.
75. English, D., A. T. Kovala, Z. Welch, K. A. Harvey, R. A. Siddiqui, D. N. Brindley, and J. G. Garcia. 1999. Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J. Hematother. Stem Cell Res. 8: 627-634.
76. Siess, W., K. J. Zangl, M. Essler, M. Bauer, R. Brandl, C. Corrinth, R. Bittman, G. Tigyi, and M. Aepfelbacher. 1999. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 96: 6931-6936.
77. Ishii, I., N. Fukushima, X. Ye, and J. Chun. 2004. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73: 321-354.
78. Anliker, B., and J. Chun. 2004. Cell surface receptors in lysophospholipid signaling. Semin. Cell Dev. Biol. 15: 457-465.
79. Pilquil, C., J. Dewald, A. Cherney, I. Gorshkova, G. Tigyi, D. English, V. Natarajan, and D. N. Brindley. 2006. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fi broblast migration by controlling phospholipase D2-dependent phosphatidate generation. J. Biol. Chem. 281: 38418-38429.
80. Lee, S. J., G. Leoni, P. A. Neumann, J. Chun, A. Nusrat, and C. C. Yun. 2013. Distinct phospholipase C-beta isozymes mediate lysophosphatidic acid receptor 1 effects on intestinal epithelial homeostasis and wound closure. Mol. Cell. Biol. 33: 2016-2028.
81. Tigyi, G., L. Hong, M. Yakubu, H. Parfenova, M. Shibata, and C. W. Leffl er. 1995. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am. J. Physiol. 268: H2048-H2055.
82. Ruisanchez, Á., P. Dancs, M. Keŕk, T. Ńmeth, B. Faragó, A. Balogh, R. Patil, B. L. Jennings, K. Liliom, K. U. Malik, et al. 2014. Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. FASEB J. 28: 880-890.
83. Davenport, A. P., S. P. Alexander, J. L. Sharman, A. J. Pawson, H. E. Benson, A. E. Monaghan, W. C. Liew, C. P. Mpamhanga, T. I. Bonner, R. R. Neubig, et al. 2013. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev. 65: 967-986.
84. Contos, J. J., and J. Chun. 1998. Complete cDNA sequence, genomic structure, and chromosomal localization of the LPA receptor gene, lpA1/vzg-1/Gpcr26. Genomics. 51: 364-378.
85. Young, J. K., B. T. Clayton, A. Kikonyogo, T. C. Pham, and A. L. Parrill. 2013. Structural characterization of an LPA1 second extracellular loop mimetic with a self-assembling coiled-coil folding constraint. Int. J. Mol. Sci. 14: 2788-2807.
86. Valentine, W. J., J. I. Fells, D. H. Perygin, S. Mujahid, K. Yokoyama, Y. Fujiwara, R. Tsukahara, J. R. Van Brocklyn, A. L. Parrill, and G. Tigyi. 2008. Subtype-specifi c residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. J. Biol. Chem. 283: 12175-12187.
87. Contos, J. J., I. Ishii, and J. Chun. 2000. Lysophosphatidic acid receptors. Mol. Pharmacol. 58: 1188-1196.
88. Ye, X. 2008. Lysophospholipid signaling in the function and pathology of the reproductive system. Hum. Reprod. Update. 14: 519-536.
89. Ohuchi, H., A. Hamada, H. Matsuda, A. Takagi, M. Tanaka, J. Aoki, H. Arai, and S. Noji. 2008. Expression patterns of the lysophospholipid receptor genes during mouse early development. Dev. Dyn. 237: 3280-3294.
90. Contos, J. J., N. Fukushima, J. A. Weiner, D. Kaushal, and J. Chun. 2000. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. USA. 97: 13384-13389.
91. Allard, J., S. Barron, J. Diaz, C. Lubetzki, B. Zalc, J. C. Schwartz, and P. Sokoloff. 1998. A rat G protein-coupled receptor selectively expressed in myelin-forming cells. Eur. J. Neurosci. 10: 1045-1053.
92. Weiner, J. A., J. H. Hecht, and J. Chun. 1998. Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J. Comp. Neurol. 398: 587-598.
93. Estivill-Torrús, G., P. Llebrez-Zayas, E. Matas-Rico, L. Santin, C. Pedraza, I. De Diego, I. Del Arco, P. Fernández-Llebrez, J. Chun, and F. R. De Fonseca. 2008. Absence of LPA1 signaling results in defective cortical development. Cereb. Cortex. 18: 938-950.
94. Harrison, S. M., C. Reavill, G. Brown, J. T. Brown, J. E. Cluderay, B. Crook, C. H. Davies, L. A. Dawson, E. Grau, C. Heidbreder, et al. 2003. LPA1 receptor-defi cient mice have phenotypic changes observed in psychiatric disease. Mol. Cell. Neurosci. 24: 1170-1179.
95. Kingsbury, M. A., S. K. Rehen, J. J. Contos, C. M. Higgins, and J. Chun. 2003. Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat. Neurosci. 6: 1292-1299.
96. Campbell, D. S., and C. E. Holt. 2001. Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron. 32: 1013-1026.
97. Fukushima, N., J. A. Weiner, and J. Chun. 2000. Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev. Biol. 228: 6-18.
98. Yuan, X. B., M. Jin, X. Xu, Y. Q. Song, C. P. Wu, M. M. Poo, and S. Duan. 2003. Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat. Cell Biol. 5: 38-45.
99. Fukushima, N., J. A. Weiner, D. Kaushal, J. J. Contos, S. K. Rehen, M. A. Kingsbury, K. Y. Kim, and J. Chun. 2002. Lysophosphatidic acid infl uences the morphology and motility of young, postmitotic cortical neurons. Mol. Cell. Neurosci. 20: 271-282.
100. Weiner, J. A., N. Fukushima, J. J. Contos, S. S. Scherer, and J. Chun. 2001. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J. Neurosci. 21: 7069-7078.
101. Jalink, K., T. Eichholtz, F. R. Postma, E. J. van Corven, and W. H. Moolenaar. 1993. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ. 4: 247-255.
102. Tigyi, G., D. J. Fischer, A. Sebok, C. Yang, D. L. Dyer, and R. Miledi. 1996. Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho. J. Neurochem. 66: 537-548.
103. Holtsberg, F. W., M. R. Steiner, A. J. Bruce-Keller, J. N. Keller, M. P. Mattson, J. C. Moyers, and S. M. Steiner. 1998. Lysophosphatidic acid and apoptosis of nerve growth factor-differentiated PC12 cells. J. Neurosci. Res. 53: 685-696.
104. Zheng, Z. Q., X. J. Fang, and J. T. Qiao. 2004. Dual action of lysophosphatidic acid in cultured cortical neurons: survival and apoptogenic. Sheng Li Xue Bao. 56: 163-171.
105. Steiner, M. R., F. W. Holtsberg, J. N. Keller, M. P. Mattson, and S. M. Steiner. 2000. Lysophosphatidic acid induction of neuronal apoptosis and necrosis. Ann. N. Y. Acad. Sci. 905: 132-141.
106. Fukushima, N., Y. Kimura, and J. Chun. 1998. A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid. Proc. Natl. Acad. Sci. USA. 95: 6151-6156.
107. Svetlov, S. I., T. N. Ignatova, K. K. Wang, R. L. Hayes, D. English, and V. G. Kukekov. 2004. Lysophosphatidic acid induces clonal generation of mouse neurospheres via proliferation of Sca-1-and AC133-positive neural progenitors. Stem Cells Dev. 13: 685-693.
108. Lloyd, B., Q. Tao, S. Lang, and C. Wylie. 2005. Lysophosphatidic acid signaling controls cortical actin assembly and cytoarchitecture in Xenopus embryos. Development. 132: 805-816.
109. Varsano, T., V. Taupin, L. Guo, O. Y. Baterina, Jr., and M. G. Farquhar. 2012. The PDZ protein GIPC regulates traffi cking of the LPA1 receptor from APPL signaling endosomes and attenuates the cell's response to LPA. PLoS ONE. 7: e49227.
110. Yu, F. X., B. Zhao, N. Panupinthu, J. L. Jewell, I. Lian, L. H. Wang, J. Zhao, H. Yuan, K. Tumaneng, H. Li, et al. 2012. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 150: 780-791.
111. Cai, H., and Y. Xu. 2013. The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun. Signal. 11: 31.
112. Matas-Rico, E., B. García-Diaz, P. Llebrez-Zayas, D. López-Barroso, L. Santín, C. Pedraza, A. Smith-Fernández, P. Fernández-Llebrez, T. Tellez, M. Redondo, et al. 2008. Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Mol. Cell. Neurosci. 39: 342-355.
113. Pedraza, C., J. Sanchez-Lopez, E. Castilla-Ortega, C. Rosell-Valle, E. Zambrana-Infantes, M. Garcia-Fernandez, F. Rodriguez de Fonseca, J. Chun, L. J. Santin, and G. Estivill-Torrus. Fear extinction and acute stress reactivity reveal a role of LPA receptor in regulating emotional-like behaviors. Brain Struct. Funct. Epub ahead of print. June 18, 2013; doi:10. 1007/s00429-013-0592- 9.
114. Castilla-Ortega, E., C. Hoyo-Becerra, C. Pedraza, J. Chun, F. Rodriguez De Fonseca, G. Estivill-Torrus, and L. J. Santin. 2011. Aggravation of chronic stress effects on hippocampal neurogenesis and spatial memory in LPA(1) receptor knockout mice. PLoS ONE. 6: e25522.
115. van Boxtel, R., B. Vroling, P. Toonen, I. J. Nijman, H. van Roekel, M. Verheul, C. Baakman, V. Guryev, G. Vriend, and E. Cuppen. 2011. Systematic generation of in vivo G protein-coupled receptor mutants in the rat. Pharmacogenomics J. 11: 326-336.
116. Nedergaard, M., B. Ransom, and S. A. Goldman. 2003. New roles for astrocytes: redefi ning the functional architecture of the brain. Trends Neurosci. 26: 523-530.
117. Cervera, P., M. Tirard, S. Barron, J. Allard, S. Trottier, J. Lacombe, C. Daumas-Duport, and P. Sokoloff. 2002. Immunohistological localization of the myelinating cell-specifi c receptor LP(A1). Glia. 38: 126-136.
118. Shano, S., R. Moriyama, J. Chun, and N. Fukushima. 2008. Lysophosphatidic acid stimulates astrocyte proliferation through LPA1. Neurochem. Int. 52: 216-220.
119. Manning, T. J., Jr., and H. Sontheimer. 1997. Bovine serum albumin and lysophosphatidic acid stimulate calcium mobilization and reversal of cAMP-induced stellation in rat spinal cord astrocytes. Glia. 20: 163-172.
120. Suidan, H. S., C. D. Nobes, A. Hall, and D. Monard. 1997. Astrocyte spreading in response to thrombin and lysophosphatidic acid is dependent on the Rho GTPase. Glia. 21: 244-252.
121. Rao, T. S., K. D. Lariosa-Willingham, F. F. Lin, E. L. Palfreyman, N. Yu, J. Chun, and M. Webb. 2003. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res. 990: 182-194.
122. Sorensen, S. D., O. Nicole, R. D. Peavy, L. M. Montoya, C. J. Lee, T. J. Murphy, S. F. Traynelis, and J. R. Hepler. 2003. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol. Pharmacol. 64: 1199-1209.
123. Sato, K., Y. Horiuchi, Y. Jin, E. Malchinkhuu, M. Komachi, T. Kondo, and F. Okajima. 2011. Unmasking of LPA1 receptormediated migration response to lysophosphatidic acid by interleukin-1-induced attenuation of Rho signaling pathways in rat astrocytes. J. Neurochem. 117: 164-174.
124. Noguchi, K., D. Herr, T. Mutoh, and J. Chun. 2009. Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9: 15-23.
125. Spohr, T. C., J. W. Choi, S. E. Gardell, D. R. Herr, S. K. Rehen, F. C. Gomes, and J. Chun. 2008. Lysophosphatidic acid receptordependent secondary effects via astrocytes promote neuronal differentiation. J. Biol. Chem. 283: 7470-7479. [Erratum. 2009. J. Biol. Chem. 284: 36720.
126. de Sampaio e Spohr, T. C. L., R. S. Dezonne, S. K. Rehen, and F. C. Gomes. 2011. Astrocytes treated by lysophosphatidic acid induce axonal outgrowth of cortical progenitors through extracellular matrix protein and epidermal growth factor signaling pathway. J. Neurochem. 119: 113-123.
127. Furukawa, A., K. Kita, M. Toyomoto, S. Fujii, S. Inoue, K. Hayashi, and K. Ikeda. 2007. Production of nerve growth factor enhanced in cultured mouse astrocytes by glycerophospholipids, sphingolipids, and their related compounds. Mol. Cell. Biochem. 305: 27-34.
128. Yu, N., K. D. Lariosa-Willingham, F. F. Lin, M. Webb, and T. S. Rao. 2004. Characterization of lysophosphatidic acid and sphingosine-1-phosphate- mediated signal transduction in rat cortical oligodendrocytes. Glia. 45: 17-27.
129. Stankoff, B., S. Barron, J. Allard, G. Barbin, F. Noel, M. S. Aigrot, J. Premont, P. Sokoloff, B. Zalc, and C. Lubetzki. 2002. Oligodendroglial expression of Edg-2 receptor: developmental analysis and pharmacological responses to lysophosphatidic acid. Mol. Cell. Neurosci. 20: 415-428.
130. Dawson, J., N. Hotchin, S. Lax, and M. Rumsby. 2003. Lysophosphatidic acid induces process retraction in CG-4 line oligodendrocytes and oligodendrocyte precursor cells but not in differentiated oligodendrocytes. J. Neurochem. 87: 947-957.
131. Nogaroli, L., L. M. Yuelling, J. Dennis, K. Gorse, S. G. Payne, and B. Fuss. 2009. Lysophosphatidic acid can support the formation of membranous structures and an increase in MBP mRNA levels in differentiating oligodendrocytes. Neurochem. Res. 34: 182-193.
132. Kobashi, H., T. Yaoi, R. Oda, S. Okajima, H. Fujiwara, T. Kubo, and S. Fushiki. 2006. Lysophospholipid receptors are differentially expressed in rat terminal Schwann cells, as revealed by a single cell rt-PCR and in situ hybridization. Acta Histochem. Cytochem. 39: 55-60.
133. Weiner, J. A., and J. Chun. 1999. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc. Natl. Acad. Sci. USA. 96: 5233-5238.
134. Li, Y., M. I. Gonzalez, J. L. Meinkoth, J. Field, M. G. Kazanietz, and G. I. Tennekoon. 2003. Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells. J. Biol. Chem. 278: 9585-9591.
135. Anliker, B., J. W. Choi, M. E. Lin, S. E. Gardell, R. R. Rivera, G. Kennedy, and J. Chun. 2013. Lysophosphatidic acid (LPA) and its receptor, LPA1, infl uence embryonic Schwann cell migration, myelination, and cell-to-axon segregation. Glia. 61: 2009-2022.
136. Contos, J. J., and J. Chun. 2000. Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identifi cation of a frameshift mutation in a previously characterized cDNA. Genomics. 64: 155-169.
137. Diez-Roux, G., S. Banfi, M. Sultan, L. Geffers, S. Anand, D. Rozado, A. Magen, E. Canidio, M. Pagani, I. Peluso, et al. 2011. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol. 9: e1000582.
138. Dubin, A. E., D. R. Herr, and J. Chun. 2010. Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J. Neurosci. 30: 7300-7309.
139. Magdaleno, S., P. Jensen, C. L. Brumwell, A. Seal, K. Lehman, A. Asbury, T. Cheung, T. Cornelius, D. M. Batten, C. Eden, et al. 2006. BGEM: an in situ hybridization database of gene expression in the embryonic and adult mouse nervous system. PLoS Biol. 4: e86.
140. Choi, J. W., D. R. Herr, K. Noguchi, Y. C. Yung, C. W. Lee, T. Mutoh, M. E. Lin, S. T. Teo, K. E. Park, A. N. Mosley, et al. 2010. LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50: 157-186.
141. Lai, Y. J., C. S. Chen, W. C. Lin, and F. T. Lin. 2005. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol. Cell. Biol. 25: 5859-5868.
142. Lai, Y. J., W. C. Lin, and F. T. Lin. 2007. PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J. Biol. Chem. 282: 24381-24387.
143. Lin, F. T., and Y. J. Lai. 2008. Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated proteinprotein interactions. Biochim. Biophys. Acta. 1781: 558-562.
144. Komachi, M., H. Tomura, E. Malchinkhuu, M. Tobo, C. Mogi, T. Yamada, T. Kimura, A. Kuwabara, H. Ohta, D. S. Im, et al. 2009. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis. 30: 457-465.
145. Gschwind, A., E. Zwick, N. Prenzel, M. Leserer, and A. Ullrich. 2001. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene. 20: 1594-1600.
146. Yang, A. H., I. Ishii, and J. Chun. 2002. In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim. Biophys. Acta. 1582: 197-203.
147. Inoue, M., M. H. Rashid, R. Fujita, J. J. Contos, J. Chun, and H. Ueda. 2004. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med. 10: 712-718.
148. Trimbuch, T., P. Beed, J. Vogt, S. Schuchmann, N. Maier, M. Kintscher, J. Breustedt, M. Schuelke, N. Streu, O. Kieselmann, et al. 2009. Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling. Cell. 138: 1222-1235.
149. Panchatcharam, M., S. Miriyala, F. Yang, M. Rojas, C. End, C. Vallant, A. Dong, K. Lynch, J. Chun, A. J. Morris, et al. 2008. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 103: 662-670.
150. Sarker, M. H., D-E. Hu, and P. A. Fraser. 2010. Regulation of cerebromicrovascular permeability by lysophosphatidic acid. Microcirculation. 17: 39-46.
151. Subramanian, P., E. Karshovska, P. Reinhard, R. T. A. Megens, Z. Zhou, S. Akhtar, U. Schumann, X. Li, M. van Zandvoort, C. Ludin, et al. 2010. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ. Res. 107: 96-105.
152. Panther, E., M. Idzko, S. Corinti, D. Ferrari, Y. Herouy, M. Mockenhaupt, S. Dichmann, P. Gebicke-Haerter, F. Di Virgilio, G. Girolomoni, et al. 2002. The infl uence of lysophosphatidic acid on the functions of human dendritic cells. J. Immunol. 169: 4129-4135.
153. Chen, R., J. Roman, J. Guo, E. West, J. McDyer, M. A. Williams, and S. N. Georas. 2006. Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. Stem Cells Dev. 15: 797-804.
154. Oh, D. Y., J. M. Yoon, M. J. Moon, J. I. Hwang, H. Choe, J. Y. Lee, J. I. Kim, S. Kim, H. Rhim, D. K. O'Dell, et al. 2008. Identifi cation of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J. Biol. Chem. 283: 21054-21064.
155. Zheng, Y., Y. Kong, and E. J. Goetzl. 2001. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J. Immunol. 166: 2317-2322.
156. Zheng, Y., J. K. Voice, Y. Kong, and E. J. Goetzl. 2000. Altered expression and functional profi le of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. FASEB J. 14: 2387-2389.
157. Rubenfeld, J., J. Guo, N. Sookrung, R. Chen, W. Chaicumpa, V. Casolaro, Y. Zhao, V. Natarajan, and S. Georas. 2006. Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L66-L74.
158. Chan, L. C., W. Peters, Y. Xu, J. Chun, R. V. Farese, Jr., and S. Cases. 2007. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J. Leukoc. Biol. 82: 1193-1200.
159. Emo, J., N. Meednu, T. J. Chapman, F. Rezaee, M. Balys, T. Randall, T. Rangasamy, and S. N. Georas. 2012. Lpa2 is a negative regulator of both dendritic cell activation and murine models of allergic lung infl ammation. J. Immunol. 188: 3784-3790.
160. Im, D. S., C. E. Heise, M. A. Harding, S. R. George, B. F. O'Dowd, D. Theodorescu, and K. R. Lynch. 2000. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57: 753-759.
161. Ishii, I., J. J. Contos, N. Fukushima, and J. Chun. 2000. Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol. Pharmacol. 58: 895-902.
162. Sonoda, H., J. Aoki, T. Hiramatsu, M. Ishida, K. Bandoh, Y. Nagai, R. Taguchi, K. Inoue, and H. Arai. 2002. A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J. Biol. Chem. 277: 34254-34263.
163. Ye, X., K. Hama, J. J. Contos, B. Anliker, A. Inoue, M. K. Skinner, H. Suzuki, T. Amano, G. Kennedy, H. Arai, et al. 2005. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature. 435: 104-108.
164. Liszewska, E., P. Reinaud, O. Dubois, and G. Charpigny. 2012. Lysophosphatidic acid receptors in ovine uterus during estrous cycle and early pregnancy and their regulation by progesterone. Domest. Anim. Endocrinol. 42: 31-42.
165. Hama, K., J. Aoki, K. Bandoh, A. Inoue, T. Endo, T. Amano, H. Suzuki, and H. Arai. 2006. Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. Life Sci. 79: 1736-1740.
166. Tokumura, A., M. Miyake, Y. Nishioka, S. Yamano, T. Aono, and K. Fukuzawa. 1999. Production of lysophosphatidic acids by lysophospholipase D in human follicular fl uids of in vitro fertilization patients. Biol. Reprod. 61: 195-199.
167. Iwasawa, Y., T. Fujii, T. Nagamatsu, K. Kawana, S. Okudaira, S. Miura, J. Matsumoto, A. Tomio, H. Hyodo, T. Yamashita, et al. 2009. Expression of autotaxin, an ectoenzyme that produces lysophosphatidic acid, in human placenta. Am. J. Reprod. Immunol. 62: 90-95.
168. Masuda, A., T. Fujii, Y. Iwasawa, K. Nakamura, R. Ohkawa, K. Igarashi, S. Okudaira, H. Ikeda, S. Kozuma, J. Aoki, et al. 2011. Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. Clin. Chim. Acta. 412: 1944-1950.
169. Lai, S. L., W. L. Yao, K. C. Tsao, A. J. Houben, H. M. Albers, H. Ovaa, W. H. Moolenaar, and S. J. Lee. 2012. Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafi sh. Development. 139: 4439-4448.
170. Lee, C. W., R. Rivera, A. E. Dubin, and J. Chun. 2007. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J. Biol. Chem. 282: 4310-4317.
171. Yanagida, K., S. Ishii, F. Hamano, K. Noguchi, and T. Shimizu. 2007. LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J. Biol. Chem. 282: 5814-5824.
172. Rhee, H. J., J. S. Nam, Y. Sun, M. J. Kim, H. K. Choi, D. H. Han, N. H. Kim, and S. O. Huh. 2006. Lysophosphatidic acid stimulates cAMP accumulation and cAMP response element-binding protein phosphorylation in immortalized hippocampal progenitor cells. Neuroreport. 17: 523-526.
173. Lee, Z., C. T. Cheng, H. Zhang, M. A. Subler, J. Wu, A. Mukherjee, J. J. Windle, C. K. Chen, and X. Fang. 2008. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol. Biol. Cell. 19: 5435-5445.
174. Mansell, J. P., M. Barbour, C. Moore, M. Nowghani, M. Pabbruwe, T. Sjostrom, and A. W. Blom. 2010. The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces. Biomaterials. 31: 199-206.
175. Liu, S., M. Umezu-Goto, M. Murph, Y. Lu, W. Liu, F. Zhang, S. Yu, L. C. Stephens, X. Cui, G. Murrow, et al. 2009. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 15: 539-550.
176. Gennero, I., S. Laurencin-Dalicieux, F. Conte-Auriol, F. Briand-Mesange, D. Laurencin, J. Rue, N. Beton, N. Malet, M. Mus, A. Tokumura, et al. 2011. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone. 49: 395-403.
177. Liu, Y. B., Y. Kharode, P. V. Bodine, P. J. Yaworsky, J. A. Robinson, and J. Billiard. 2010. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J. Cell. Biochem. 109: 794-800.
178. Sumida, H., K. Noguchi, Y. Kihara, M. Abe, K. Yanagida, F. Hamano, S. Sato, K. Tamaki, Y. Morishita, M. R. Kano, et al. 2010. LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood. 116: 5060-5070.
179. Morishige, J., Y. Uto, H. Hori, K. Satouchi, T. Yoshiomoto, and A. Tokumura. 2013. Lysophosphatidic acid produced by hen egg white lysophospholipase D induces vascular development on extraembryonic membranes. Lipids. 48: 251-262.
180. Amisten, S., O. O. Braun, A. Bengtsson, and D. Erlinge. 2008. Gene expression profi ling for the identifi cation of G-protein coupled receptors in human platelets. Thromb. Res. 122: 47-57.
181. Lundequist, A., and J. A. Boyce. 2011. LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1-release. PLoS ONE. 6: e18192.
182. Williams, J. R., A. L. Khandoga, P. Goyal, J. I. Fells, D. H. Perygin, W. Siess, A. L. Parrill, G. Tigyi, and Y. Fujiwara. 2009. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J. Biol. Chem. 284: 17304-17319.
183. Jongsma, M., E. Matas-Rico, A. Rzadkowski, K. Jalink, and W. H. Moolenaar. 2011. LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS ONE. 6: e29260.
184. Lin, S., S. Yeruva, P. He, A. K. Singh, H. Zhang, M. Chen, G. Lamprecht, H. R. de Jonge, M. Tse, M. Donowitz, et al. 2010. Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fl uid absorption via LPA(5) and NHERF2. Gastroenterology. 138: 649-658.
185. Kaplan, M. H., D. I. Smith, and R. S. Sundick. 1993. Identifi cation of a G protein coupled receptor induced in activated T cells. J. Immunol. 151: 628-636.
186. Webb, T. E., M. G. Kaplan, and E. A. Barnard. 1996. Identifi cation of 6H1 as a P2Y purinoceptor: P2Y5. Biochem. Biophys. Res. Commun. 219: 105-110.
187. Lee, M., S. Choi, G. Hallden, S. J. Yo, D. Schichnes, and G. W. Aponte. 2009. P2Y5 is a G(alpha)i, G(alpha) 12/13 G proteincoupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G641-G654.
188. Shimomura, Y., M. C. Garzon, L. Kristal, L. Shapiro, and A. M. Christiano. 2009. Autosomal recessive woolly hair with hypotrichosis caused by a novel homozygous mutation in the P2RY5 gene. Exp. Dermatol. 18: 218-221.
189. Nahum, S., F. Morice-Picard, A. Taieb, and E. Sprecher. 2011. A novel mutation in LPAR6 causes autosomal recessive hypotrichosis of the scalp. Clin. Exp. Dermatol. 36: 188-194.
190. Pasternack, S. M., I. von Kugelgen, M. Muller, V. Oji, H. Traupe, E. Sprecher, M. M. Nothen, A. R. Janecke, and R. C. Betz. 2009. In vitro analysis of LIPH mutations causing hypotrichosis simplex: evidence confi rming the role of lipase H and lysophosphatidic acid in hair growth. J. Invest. Dermatol. 129: 2772-2776.
191. Shinkuma, S., M. Akiyama, A. Inoue, J. Aoki, K. Natsuga, T. Nomura, K. Arita, R. Abe, K. Ito, H. Nakamura, et al. 2010. Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability of PA-PLA1alpha in autosomal recessive hypotrichosis. Hum. Mutat. 31: 602-610.
192. Inoue, A., N. Arima, J. Ishiguro, G. D. Prestwich, H. Arai, and J. Aoki. 2011. LPA-producing enzyme PA-PLA(1)-regulates hair follicle development by modulating EGFR signalling. EMBO J. 30: 4248-4260.
193. Jiang, G., Y. Xu, Y. Fujiwara, T. Tsukahara, R. Tsukahara, J. Gajewiak, G. Tigyi, and G. D. Prestwich. 2007. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem. 2: 679-690.
194. Gajewiak, J., R. Tsukahara, Y. Fujiwara, G. Tigyi, and G. D. Prestwich. 2008. Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid.org. Lett. 10: 1111-1114.
195. Zhang, H., X. Xu, J. Gajewiak, R. Tsukahara, Y. Fujiwara, J. Liu, J. I. Fells, D. Perygin, A. L. Parrill, G. Tigyi, et al. 2009. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69: 5441-5449.
196. Schleicher, S. M., D. K. Thotala, A. G. Linkous, R. Hu, K. M. Leahy, E. M. Yazlovitskaya, and D. E. Hallahan. 2011. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE. 6: e22182.
197. Swaney, J. S., C. Chapman, L. D. Correa, K. J. Stebbins, R. A. Bundey, P. C. Prodanovich, P. Fagan, C. S. Baccei, A. M. Santini, J. H. Hutchinson, et al. 2010. A novel, orally active LPA(1) receptor antagonist inhibits lung fi brosis in the mouse bleomycin model. Br. J. Pharmacol. 160: 1699-1713.
198. Boucharaba, A., C. M. Serre, J. Guglielmi, J. C. Bordet, P. Clezardin, and O. Peyruchaud. 2006. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA. 103: 9643-9648.
199. Okusa, M. D., H. Ye, L. Huang, L. Sigismund, T. Macdonald, and K. R. Lynch. 2003. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 285: F565-F574.
200. Moll, S., L. Chaykovska, M. Meier, D. C. Budd, I. Formentini, S. Pomposiello, and M. Prunotto. 2013. Targeting the epithelial cells in fi brosis: a new concept for an old disease. Drug Discov. Today. 18: 582-591.
201. Hultman, C. M., P. Sparen, N. Takei, R. M. Murray, and S. Cnattingius. 1999. Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case-control study. BMJ. 318: 421-426.
202. Vukojeviæ, M., I. Soldo, and D. Graniæ. 2009. Risk factors associated with cerebral palsy in newborns. Coll. Antropol. 33(Suppl 2): 199-201.
203. Whitelaw, A. 2001. Intraventricular haemorrhage and posthaemorrhagic hydrocephalus: pathogenesis, prevention and future interventions. Semin. Neonatol. 6: 135-146.
204. Herr, K. J., D. R. Herr, C. W. Lee, K. Noguchi, and J. Chun. 2011. Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling. Proc. Natl. Acad. Sci. USA. 108: 15444-15449.
205. Aquilina, K., C. Hobbs, S. Cherian, A. Tucker, H. Porter, A. Whitelaw, and M. Thoresen. 2007. A neonatal piglet model of intraventricular hemorrhage and posthemorrhagic ventricular dilation. J. Neurosurg. 107: 126-136.
206. Lodhia, K. R., P. Shakui, and R. F. Keep. 2006. Hydrocephalus in a rat model of intraventricular hemorrhage. Acta Neurochir. Suppl. 96: 207-211.
207. Deleted in proof.
208. Byrne, M., E. Agerbo, B. Bennedsen, W. W. Eaton, and P. B. Mortensen. 2007. Obstetric conditions and risk of fi rst admission with schizophrenia: a Danish national register based study. Schizophr. Res. 97: 51-59.
209. Brimacombe, M., X. Ming, and M. Lamendola. 2007. Prenatal and birth complications in autism. Matern. Child Health J. 11: 73-79.
210. Roberts, C., P. Winter, C. S. Shilliam, Z. A. Hughes, C. Langmead, P. R. Maycox, and L. A. Dawson. 2005. Neurochemical changes in LPA1 receptor defi cient mice-a putative model of schizophrenia. Neurochem. Res. 30: 371-377.
211. Musazzi, L., E. Di Daniel, P. Maycox, G. Racagni, and M. Popoli. 2010. Abnormalities in -/-CaMKII and related mechanisms suggest synaptic dysfunction in hippocampus of LPA1 receptor knockout mice. Int. J. Neuropsychopharmacol. 14: 941-953.
212. Cunningham, M. O., J. Hunt, S. Middleton, F. E. LeBeau, M. J. Gillies, C. H. Davies, P. R. Maycox, M. A. Whittington, and C. Racca. 2006. Region-specifi c reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J. Neurosci. 26: 2767-2776. [Erratum. 2006. J. Neurosci. 26: table of contents. ]
213. Santin, L. J., A. Bilbao, C. Pedraza, E. Matas-Rico, D. Lopez-Barroso, E. Castilla-Ortega, J. Sanchez-Lopez, R. Riquelme, I. Varela-Nieto, P. de la Villa, et al. 2009. Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory defi cits. Genes Brain Behav. 8: 772-784.
214. Castilla-Ortega, E., J. Sánchez-López, C. Hoyo-Becerra, E. Matas-Rico, E. Zambrana-Infantes, J. Chun, F. R. De Fonseca, C. Pedraza, G. Estivill-Torrús, and L. J. Santin. 2010. Exploratory, anxiety and spatial memory impairments are dissociated in mice lacking the LPA1 receptor. Neurobiol. Learn. Mem. 94: 73-82.
215. Ong, W. Y., T. Farooqui, and A. A. Farooqui. 2010. Involvement of cytosolic phospholipase A2, calcium independent phospholipase A2 and plasmalogen selective phospholipase A2 in neurodegenerative and neuropsychiatric conditions. Curr. Med. Chem. 17: 2746-2763.
216. Renbäck, K., M. Inoue, and H. Ueda. 1999. Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice. Neurosci. Lett. 270: 59-61.
217. Lin, M. E., R. R. Rivera, and J. Chun. 2012. Targeted deletion of LPA5 identifi es novel roles for lysophosphatidic acid signaling in development of neuropathic pain. J. Biol. Chem. 287: 17608-17617.
218. Fujita, R., N. Kiguchi, and H. Ueda. 2007. LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem. Int. 50: 351-355.
219. Inoue, M., W. Xie, Y. Matsushita, J. Chun, J. Aoki, and H. Ueda. 2008. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience. 152: 296-298.
220. Inoue, M., L. Ma, J. Aoki, J. Chun, and H. Ueda. 2008. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol. Pain. 4: 6.
221. Ma, L., H. Uchida, J. Nagai, M. Inoue, J. Chun, J. Aoki, and H. Ueda. 2009. Lysophosphatidic acid-3 receptor-mediated feedforward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain. Mol. Pain. 5: 64.
222. Kakiuchi, Y., J. Nagai, M. Gotoh, H. Hotta, H. Murofushi, T. Ogawa, H. Ueda, and K. Murakami-Murofushi. 2011. Antinociceptive signaleffect of cyclic phosphatidic acid and its derivative on animal models of acute and chronic pain. Mol. Pain. 7: 33.
223. Ma, L., J. Nagai, J. Chun, and H. Ueda. 2013. An LPA species (18:1 LPA) plays key roles in the self-amplifi cation of spinal LPA production in the peripheral neuropathic pain model. Mol. Pain. 9: 29.
224. Siess, W. 2002. Athero-and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta. 1582: 204-215.
225. Lin, C. I., C. N. Chen, J. H. Chen, and H. Lee. 2006. Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J. Cell. Biochem. 99: 1216-1232.
226. Palmetshofer, A., S. C. Robson, and V. Nehls. 1999. Lysophosphatidic acid activates nuclear factor kappa B and induces proinfl ammatory gene expression in endothelial cells. Thromb. Haemost. 82: 1532-1537.
227. Chang, C. L., H. Y. Hsu, H. Y. Lin, W. Chiang, and H. Lee. 2008. Lysophosphatidic acid-induced oxidized low-density lipoprotein uptake is class A scavenger receptor-dependent in macrophages. Prostaglandins Other Lipid Mediat. 87: 20-25.
228. Neidlinger, N. A., S. K. Larkin, A. Bhagat, G. P. Victorino, and F. A. Kuypers. 2006. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J. Biol. Chem. 281: 775-781.
229. Rother, E., R. Brandl, D. L. Baker, P. Goyal, H. Gebhard, G. Tigyi, and W. Siess. 2003. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation. 108: 741-747.
230. Willoughby, S., A. Holmes, and J. Loscalzo. 2002. Platelets and cardiovascular disease. Eur. J. Cardiovasc. Nurs. 1: 273-288.
231. Li, Z-G., Z-C. Yu, D-Z. Wang, W-P. Ju, X. Zhan, Q-Z. Wu, X-J. Wu, H-M. Cong, and H-H. Man. 2008. Infl uence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol. Res. 30: 366-369.
232. van Nieuw Amerongen, G. P., M. A. Vermeer, and V. W. van Hinsbergh. 2000. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler. Thromb. Vasc. Biol. 20: E127-E133.
233. Karliner, J. S., N. Honbo, K. Summers, M. O. Gray, and E. J. Goetzl. 2001. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 33: 1713-1717.
234. Chen, J., A. R. Baydoun, R. Xu, L. Deng, X. Liu, W. Zhu, L. Shi, X. Cong, S. Hu, and X. Chen. 2008. Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivationinduced apoptosis. Stem Cells. 26: 135-145.
235. Savitz, S. I., M. S. Dhallu, S. Malhotra, A. Mammis, L. C. Ocava, P. S. Rosenbaum, and D. M. Rosenbaum. 2006. EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury. Brain Res. 1118: 168-175.
236. Brault, S., F. Gobeil, Jr., A. Fortier, J. C. Honore, J. S. Joyal, P. S. Sapieha, A. Kooli, E. Martin, P. Hardy, A. Ribeiro-da-Silva, et al. 2007. Lysophosphatidic acid induces endothelial cell death by modulating the redox environment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292: R1174-R1183.
237. Tabuchi, S., K. Kume, M. Aihara, and T. Shimizu. 2000. Expression of lysophosphatidic acid receptor in rat astrocytes: mitogenic effect and expression of neurotrophic genes. Neurochem. Res. 25: 573-582.
238. Yin, Z., L. D. Carbone, M. Gotoh, A. Postlethwaite, A. L. Bolen, G. J. Tigyi, K. Murakami-Murofushi, and M. A. Watsky. 2010. Lysophosphatidic acid-activated Cl-current activity in human systemic sclerosis skin fi broblasts. Rheumatology. 49: 2290-2297.
239. Tokumura, A., L. D. Carbone, Y. Yoshioka, J. Morishige, M. Kikuchi, A. Postlethwaite, and M. A. Watsky. 2009. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine-1-phosphate in systemic sclerosis. Int. J. Med. Sci. 6: 168-176.
240. Park, G. Y., Y. G. Lee, E. Berdyshev, S. Nyenhuis, J. Du, P. Fu, I. A. Gorshkova, Y. Li, S. Chung, M. Karpurapu, et al. 2013. Autotaxin production of lysophosphatidic acid mediates allergic asthmatic infl ammation. Am. J. Respir. Crit. Care Med. 188: 928-940.
241. Zhao, C., M. J. Fernandes, G. D. Prestwich, M. l. Turgeon, J. Di Battista, T. Clair, P. E. Poubelle, and S. G. Bourgoin. 2008. Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis? Mol. Pharmacol. 73: 587-600.
242. Miyabe, Y., C. Miyabe, Y. Iwai, A. Takayasu, S. Fukuda, W. Yokoyama, J. Nagai, M. Jona, Y. Tokuhara, R. Ohkawa, et al. 2013. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum. 65: 2037-2047.
243. Mototani, H., A. Iida, M. Nakajima, T. Furuichi, Y. Miyamoto, T. Tsunoda, A. Sudo, A. Kotani, A. Uchida, K. Ozaki, et al. 2008. A functional SNP in EDG2 increases susceptibility to knee osteoarthritis in Japanese. Hum. Mol. Genet. 17: 1790-1797.
244. Orosa, B., S. Garcia, P. Martinez, A. Gonzalez, J. J. Gomez-Reino, and C. Conde. 2014. Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. Ann. Rheum. Dis. 73 298-305.
245. Tager, A. M., P. LaCamera, B. S. Shea, G. S. Campanella, M. Selman, Z. Zhao, V. Polosukhin, J. Wain, B. A. Karimi-Shah, N. D. Kim, et al. 2008. The lysophosphatidic acid receptor LPA1 links pulmonary fi brosis to lung injury by mediating fi broblast recruitment and vascular leak. Nat. Med. 14: 45-54.
246. Pradère, J. P., J. Klein, S. Grès, C. Guigń, E. Neau, P. Valet, D. Calise, J. Chun, J. L. Bascands, J. S. Saulnier-Blache, et al. 2007. LPA1 receptor activation promotes renal interstitial fi brosis. J. Am. Soc. Nephrol. 18: 3110-3118.
247. Sakai, N., J. Chun, J. S. Duffi eld, T. Wada, A. D. Luster, and A. M. Tager. 2013. LPA1-induced cytoskeleton reorganization drives fi brosis through CTGF-dependent fi broblast proliferation. FASEB J. 27: 1830-1846.
248. Huang, L. S., P. Fu, P. Patel, A. Harijith, T. Sun, Y. Zhao, J. G. Garcia, J. Chun, and V. Natarajan. 2013. Lysophosphatidic acid receptor 2 deficiency confers protection against bleomycininduced lung injury and fi brosis in mice. Am. J. Respir. Cell Mol. Biol. 49: 912-922.
249. Ikeda, H., Y. Yatomi, M. Yanase, H. Satoh, A. Nishihara, M. Kawabata, and K. Fujiwara. 1998. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem. Biophys. Res. Commun. 248: 436-440.
250. Wu, J., and M. A. Zern. 2000. Hepatic stellate cells: a target for the treatment of liver fi brosis. J. Gastroenterol. 35: 665-672.
251. Gan, L., J. X. Xue, X. Li, D. S. Liu, Y. Ge, P. Y. Ni, L. Deng, Y. Lu, and W. Jiang. 2011. Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fi brosis induced by irradiation. Biochem. Biophys. Res. Commun. 409: 7-13.
252. Deleted in proof.
253. Geng, H., R. Lan, P. K. Singha, A. Gilchrist, P. H. Weinreb, S. M. Violette, J. M. Weinberg, P. Saikumar, and M. A. Venkatachalam. 2012. Lysophosphatidic acid increases proximal tubule cell secretion of profi brotic cytokines PDGF-B and CTGF through LPA2-and G-q-mediated Rho and-v-6 integrin-dependent activation of TGF-. Am. J. Pathol. 181: 1236-1249.
254. Castelino, F. V., J. Seiders, G. Bain, S. F. Brooks, C. D. King, J. S. Swaney, D. S. Lorrain, J. Chun, A. D. Luster, and A. M. Tager. 2011. Amelioration of dermal fi brosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 63: 1405-1415.
255. Blackburn, J., and J. P. Mansell. 2012. The emerging role of lysophosphatidic acid (LPA) in skeletal biology. Bone. 50: 756-762.
256. Sims, S. M., N. Panupinthu, D. M. Lapierre, A. Pereverzev, and S. J. Dixon. 2013. Lysophosphatidic acid: a potential mediator of osteoblast- osteoclast signaling in bone. Biochim. Biophys. Acta. 1831: 109-116.
257. Lapierre, D. M., N. Tanabe, A. Pereverzev, M. Spencer, R. P. Shugg, S. J. Dixon, and S. M. Sims. 2010. Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival. J. Biol. Chem. 285: 25792-25801.
258. Ye, X., and J. Chun. 2010. Lysophosphatidic acid (LPA) signaling in vertebrate reproduction. Trends Endocrinol. Metab. 21: 17-24.
259. Hama, K., J. Aoki, A. Inoue, T. Endo, T. Amano, R. Motoki, M. Kanai, X. Ye, J. Chun, N. Matsuki, et al. 2007. Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. Biol. Reprod. 77: 954-959.
260. Song, H., H. Lim, B. C. Paria, H. Matsumoto, L. L. Swift, J. Morrow, J. V. Bonventre, and S. K. Dey. 2002. Cytosolic phospholipase A2alpha is crucial [correction of A2alpha defi ciency is crucial] for 'on-time' embryo implantation that directs subsequent development. Development. 129: 2879-2889.
261. Mohamed, O. A., M. Jonnaert, C. Labelle-Dumais, K. Kuroda, H. J. Clarke, and D. Dufort. 2005. Uterine Wnt/beta-catenin signaling is required for implantation. Proc. Natl. Acad. Sci. USA. 102: 8579-8584.
262. Woclawek-Potocka, I., J. Komiyama, J. S. Saulnier-Blache, E. Brzezicka, M. M. Bah, K. Okuda, and D. J. Skarzynski. 2009. Lysophosphatic acid modulates prostaglandin secretion in the bovine uterus. Reproduction. 137: 95-105.
263. Woclawek-Potocka, I., K. Kondraciuk, and D. J. Skarzynski. 2009. Lysophosphatidic acid stimulates prostaglandin E2 production in cultured stromal endometrial cells through LPA1 receptor. Exp. Biol. Med. (Maywood). 234: 986-993.
264. Ye, X., M. K. Skinner, G. Kennedy, and J. Chun. 2008. Agedependent loss of sperm production in mice via impaired lysophosphatidic acid signaling. Biol. Reprod. 79: 328-336.
265. Garbi, M., S. Rubinstein, Y. Lax, and H. Breitbart. 2000. Activation of protein kinase Calpha in the lysophosphatidic acid-induced bovine sperm acrosome reaction and phospholipase D1 regulation. Biol. Reprod. 63: 1271-1277.
266. Reilly, J. J. 2005. Descriptive epidemiology and health consequences of childhood obesity. Best Pract. Res. Clin. Endocrinol. Metab. 19: 327-341.
267. Reilly, J. J., and J. Kelly. 2011. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int. J. Obes. (Lond). 35: 891-898.
268. Isakson, P., A. Hammarstedt, B. Gustafson, and U. Smith. 2009. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and infl ammation. Diabetes. 58: 1550-1557.
269. Valet, P., C. Pages, O. Jeanneton, D. Daviaud, P. Barbe, M. Record, J. S. Saulnier-Blache, and M. Lafontan. 1998. Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J. Clin. Invest. 101: 1431-1438.
270. Ferry, G., E. Tellier, A. Try, S. Gres, I. Naime, M. F. Simon, M. Rodriguez, J. Boucher, I. Tack, S. Gesta, et al. 2003. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 278: 18162-18169.
271. Nobusue, H., D. Kondo, M. Yamamoto, and K. Kano. 2010. Effects of lysophosphatidic acid on the in vitro proliferation and differentiation of a novel porcine preadipocyte cell line. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 157: 401-407.
272. Boucher, J., D. Quilliot, J. P. Praderes, M. F. Simon, S. Gres, C. Guigne, D. Prevot, G. Ferry, J. A. Boutin, C. Carpene, et al. 2005. Potential involvement of adipocyte insulin resistance in obesityassociated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia. 48: 569-577.
273. Holmström, T. E., C. L. Mattsson, Y. Wang, I. Iakovleva, N. Petrovic, and J. Nedergaard. 2010. Non-transactivational, dual pathways for LPA-induced Erk1/2 activation in primary cultures of brown pre-adipocytes. Exp. Cell Res. 316: 2664-2675.
274. Simon, M. F., D. Daviaud, J. P. Pradere, S. Gres, C. Guigne, M. Wabitsch, J. Chun, P. Valet, and J. S. Saulnier-Blache. 2005. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J. Biol. Chem. 280: 14656-14662.
275. Dusaulcy, R., D. Daviaud, J. P. Pradere, S. Gres, P. Valet, and J. S. Saulnier-Blache. 2009. Altered food consumption in mice lacking lysophosphatidic acid receptor-1. J. Physiol. Biochem. 65: 345-350.
276. Yea, K., J. Kim, S. Lim, H. S. Park, K. S. Park, P. G. Suh, and S. H. Ryu. 2008. Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake. J. Mol. Med. 86: 211-220.
277. Rancoule, C., C. Attane, S. Gres, A. Fournel, R. Dusaulcy, C. Bertrand, C. Vinel, K. Treguer, M. Prentki, P. Valet, et al. 2013. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia. 56: 1394-1402.
278. Rancoule, C., R. Dusaulcy, K. Treguer, S. Gres, C. Attane, and J. S. Saulnier-Blache. 2014. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie. 96: 140-143.
279. Lin, M. E., D. R. Herr, and J. Chun. 2010. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91: 130-138.
280. Tigyi, G. 2010. Aiming drug discovery at lysophosphatidic acid targets. Br. J. Pharmacol. 161: 241-270.
281. Mutoh, T., R. Rivera, and J. Chun. 2012. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 165: 829-844.
282. Sedláková, I., J. Vávrová, J. Tošner, and L. Hanousek. 2010. Lysophosphatidic acid (LPA) a perspective marker in ovarian cancer. Tumour Biol. 32: 311-316.
283. Xu, Y., X. J. Fang, G. Casey, and G. B. Mills. 1995. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309: 933-940.
284. Nouh, M. A. A. M., X-X. Wu, H. Okazoe, H. Tsunemori, R. Haba, A. M. M. Abou-Zeid, M. D. Saleem, M. Inui, M. Sugimoto, J. Aoki, et al. 2009. Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression. Cancer Sci. 100: 1631-1638.
285. Wu, J. M., Y. Xu, N. J. Skill, H. Sheng, Z. Zhao, M. Yu, R. Saxena, and M. A. Maluccio. 2010. Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol. Cancer. 9: 71.
286. Kishi, Y., S. Okudaira, M. Tanaka, K. Hama, D. Shida, J. Kitayama, T. Yamori, J. Aoki, T. Fujimaki, and H. Arai. 2006. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J. Biol. Chem. 281: 17492-17500.
287. Lee, S. J., and C. C. Yun. 2010. Colorectal cancer cells-proliferation, survival and invasion by lysophosphatidic acid. Int. J. Biochem. Cell Biol. 42: 1907-1910.
288. Kitayama, J., D. Shida, A. Sako, M. Ishikawa, K. Hama, J. Aoki, H. Arai, and H. Nagawa. 2004. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6: R640-R646.
289. Jeong, K. J., S. Y. Park, J. H. Seo, K. B. Lee, W. S. Choi, J. W. Han, J. K. Kang, C. G. Park, Y. K. Kim, and H. Y. Lee. 2008. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp. Mol. Med. 40: 607-616.
290. Hope, J. M., F. Q. Wang, J. S. Whyte, E. V. Ariztia, W. Abdalla, K. Long, and D. A. Fishman. 2009. LPA receptor 2 mediates LPAinduced endometrial cancer invasion. Gynecol. Oncol. 112: 215-223.
291. Wang, G. L., Z. Q. Wen, W. P. Xu, Z. Y. Wang, X. L. Du, and F. Wang. 2008. Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells. Croat. Med. J. 49: 175-181.
292. Yun, C. C., H. Sun, D. Wang, R. Rusovici, A. Castleberry, R. A. Hall, and H. Shim. 2005. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am. J. Physiol. Cell Physiol. 289: C2-C11.
293. Huang, M. C., H. Y. Lee, C. C. Yeh, Y. Kong, C. J. Zaloudek, and E. J. Goetzl. 2004. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene. 23: 122-129.
294. Shida, D., X. Fang, T. Kordula, K. Takabe, S. Lepine, S. E. Alvarez, S. Milstien, and S. Spiegel. 2008. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 68: 6569-6577.
295. Zeng, Y., Y. Kakehi, M. A. Nouh, H. Tsunemori, M. Sugimoto, and X. X. Wu. 2009. Gene expression profi les of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia. Prostate. 69: 283-292.
296. Yu, S., M. M. Murph, Y. Lu, S. Liu, H. S. Hall, J. Liu, C. Stephens, X. Fang, and G. B. Mills. 2008. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst. 100: 1630-1642.
297. Masiello, L. M., J. S. Fotos, D. S. Galileo, and N. J. Karin. 2006. Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells. Bone. 39: 72-82.
298. Li, T. T., M. Alemayehu, A. I. Aziziyeh, C. Pape, M. Pampillo, L. M. Postovit, G. B. Mills, A. V. Babwah, and M. Bhattacharya. 2009. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol. Cancer Res. 7: 1064-1077.
299. Yamada, T., K. Sato, M. Komachi, E. Malchinkhuu, M. Tobo, T. Kimura, A. Kuwabara, Y. Yanagita, T. Ikeya, Y. Tanahashi, et al. 2004. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J. Biol. Chem. 279: 6595-6605.
300. Okabe, K., M. Hayashi, M. Fujii, K. Honoki, T. Mori, N. Fukushima, and T. Tsujiuchi. 2010. Mutations of lysophosphatidic acid receptor genes in human osteosarcoma cells. Pathobiology. 77: 278-282.
301. Obo, Y., T. Yamada, M. Furukawa, M. Hotta, K. Honoki, N. Fukushima, and T. Tsujiuchi. 2009. Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat. Res. 660: 47-50.
302. Shin, K. J., Y. L. Kim, S. Lee, D. K. Kim, C. Ahn, J. Chung, J. Y. Seong, and J. I. Hwang. 2009. Lysophosphatidic acid signaling through LPA receptor subtype 1 induces colony scattering of gastrointestinal cancer cells. J. Cancer Res. Clin. Oncol. 135: 45-52.
303. David, M., E. Wannecq, F. Descotes, S. Jansen, B. Deux, J. Ribeiro, C. M. Serre, S. Gres, N. Bendriss-Vermare, M. Bollen, et al. 2010. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE. 5: e9741.
304. Yang, S. Y., J. Lee, C. G. Park, S. Kim, S. Hong, H. C. Chung, S. K. Min, J. W. Han, H. W. Lee, and H. Y. Lee. 2002. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis. 19: 603-608.
305. Yang, Y., L-j. Mou, N. Liu, and M-S. Tsao. 1999. Autotaxin expression in non-small-cell lung cancer. Am. J. Respir. Cell Mol. Biol. 21: 216-222.
306. Kehlen, A., N. Englert, A. Seifert, T. Klonisch, H. Dralle, J. Langner, and C. Hoang-Vu. 2004. Expression, regulation and function of autotaxin in thyroid carcinomas. Int. J. Cancer. 109: 833-838.
307. Kazama, S., J. Kitayama, J. Aoki, K. Mori, and H. Nagawa. 2011. Immunohistochemical detection of autotaxin (ATX)/lysophospholipase D (lysoPLD) in submucosal invasive colorectal cancer. J. Gastrointest. Cancer. 42: 204-211.
308. Samadi, N., C. Gaetano, I. S. Goping, and D. N. Brindley. 2009. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene. 28: 1028-1039.
309. Houben, A. J., and W. H. Moolenaar. 2011. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 30: 557-565.
310. Jonkers, J., and W. H. Moolenaar. 2009. Mammary tumorigenesis through LPA receptor signaling. Cancer Cell. 15: 457-459.
311. Willier, S., E. Butt, and T. G. Grunewald. 2013. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol. Cell. 105: 317-333.
312. Lin, C. I., C. N. Chen, M. T. Huang, S. J. Lee, C. H. Lin, C. C. Chang, and H. Lee. 2008. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation-and EGFR transactivation-dependent mechanisms. Cell. Signal. 20: 1804-1814.
313. Sitohy, B., J. A. Nagy, and H. F. Dvorak. 2012. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 72: 1909-1914.
314. Jeon, E. S., S. C. Heo, I. H. Lee, Y. J. Choi, J. H. Park, K. U. Choi, Y. Park do, D. S. Suh, M. S. Yoon, and J. H. Kim. 2010. Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells. Exp. Mol. Med. 42: 280-293.
315. Dutta, S., F. Q. Wang, H. S. Wu, T. J. Mukherjee, and D. A. Fishman. 2011. The NF-B pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecol. Oncol. 123: 129-137.
316. Komachi, M., K. Sato, M. Tobo, C. Mogi, T. Yamada, H. Ohta, H. Tomura, T. Kimura, D. S. Im, K. Yanagida, et al. 2012. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci. 103: 1099-1104.
317. Marshall, J. C., J. W. Collins, J. Nakayama, C. E. Horak, D. J. Liewehr, S. M. Steinberg, M. Albaugh, F. Vidal-Vanaclocha, D. Palmieri, M. Barbier, et al. 2012. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J. Natl. Cancer Inst. 104: 1306-1319.
318. Beck, H. P., T. Kohn, S. Rubenstein, C. Hedberg, R. Schwandner, K. Hasslinger, K. Dai, C. Li, L. Liang, H. Wesche, et al. 2008. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg. Med. Chem. Lett. 18: 1037-1041.
319. Mirendil, H., M. E. Lin, and J. Chun. 2013. Lysophosphatidic acid (LPA) receptor signaling. In Lysophospholipid Receptors: Signaling and Biochemistry. J. Chun, T. Hla, S. Spiegel, et al., editors. Wiley, Hoboken, NJ. 1-39.
320. An, S., T. Bleu, Y. Zheng, and E. J. Goetzl. 1998. Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization. Mol. Pharmacol. 54: 881-888.
321. Liliom, K., R. Bittman, B. Swords, and G. Tigyi. 1996. N-palmitoylserine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors. Mol. Pharmacol. 50: 616-623.
322. Im, D. S. 2010. Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol. Sin. 31: 1213-1222.
323. Sugiura, T., A. Tokumura, L. Gregory, T. Nouchi, S. T. Weintraub, and D. J. Hanahan. 1994. Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor. Arch. Biochem. Biophys. 311: 358-368.
324. Durgam, G. G., T. Virag, M. D. Walker, R. Tsukahara, S. Yasuda, K. Liliom, L. A. van Meeteren, W. H. Moolenaar, N. Wilke, W. Siess, et al. 2005. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J. Med. Chem. 48: 4919-4930.
325. Markiewicz, W., K. Kaminska, M. Bogacki, T. Maslanka, and J. Jaroszewski. 2012. Participation of analogues of lysophosphatidic acid (LPA): oleoyl-sn-glycero-3-phosphate (L-alpha-LPA) and 1-oleoyl-2-O-methyl-rac- glycerophosphothionate (OMPT) in uterine smooth muscle contractility of the pregnant pigs. Pol. J. Vet. Sci. 15: 635-643.
326. Tamaruya, Y., M. Suzuki, G. Kamura, M. Kanai, K. Hama, K. Shimizu, J. Aoki, H. Arai, and M. Shibasaki. 2004. Identifying specifi c conformations by using a carbohydrate scaffold: discovery of subtype-selective LPA-receptor agonists and an antagonist. Angew. Chem. Int. Ed. Engl. 43: 2834-2837.
327. Virag, T., D. B. Elrod, K. Liliom, V. M. Sardar, A. L. Parrill, K. Yokoyama, G. Durgam, W. Deng, D. D. Miller, and G. Tigyi. 2003. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 63: 1032-1042.
328. Qian, L., Y. Xu, T. Simper, G. Jiang, J. Aoki, M. Umezu-Goto, H. Arai, S. Yu, G. B. Mills, R. Tsukahara, et al. 2006. Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. ChemMedChem. 1: 376-383.
329. Jiang, G., A. Inoue, J. Aoki, and G. D. Prestwich. 2013. Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists. Bioorg. Med. Chem. Lett. 23: 1865-1869.
330. Nikitopoulou, I., E. Kaffe, I. Sevastou, I. Sirioti, M. Samiotaki, D. Madan, G. D. Prestwich, and V. Aidinis. 2013. A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis. PLoS ONE. 8: e70941.
331. Ohta, H., K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, et al. 2003. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64: 994-1005.
332. Sato, T., K. Sugimoto, A. Inoue, S. Okudaira, J. Aoki, and H. Tokuyama. 2012. Synthesis and biological evaluation of optically active Ki16425. Bioorg. Med. Chem. Lett. 22: 4323-4326.
333. Bain, G., and J. Seiders. 2013. LPA receptor subtypes LPA1 and LPA2 as potential drug targets. In Lysophospholipid Receptors: Signaling and Biochemistry. J. Chun, T. Hla, S. Spiegel, et al., editors. Wiley, Hoboken, NJ. 681-708.
334. David, M., J. Ribeiro, F. Descotes, C. M. Serre, M. Barbier, M. Murone, P. Clezardin, and O. Peyruchaud. 2012. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol. 40: 1133-1141.
335. Fells, J. I., R. Tsukahara, Y. Fujiwara, J. Liu, D. H. Perygin, D. A. Osborne, G. Tigyi, and A. L. Parrill. 2008. Identifi cation of nonlipid LPA3 antagonists by virtual screening. Bioorg. Med. Chem. 16: 6207-6217.
336. Swaney, J. S., C. Chapman, L. D. Correa, K. J. Stebbins, A. R. Broadhead, G. Bain, A. M. Santini, J. Darlington, C. D. King, C. S. Baccei, et al. 2011. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptorselective antagonist. J. Pharmacol. Exp. Ther. 336: 693-700.
337. Deleted in proof.
338. Fischer, D. J., N. Nusser, T. Virag, K. Yokoyama, D. Wang, D. L. Baker, D. Bautista, A. L. Parrill, and G. Tigyi. 2001. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 60: 776-784.
339. Aaltonen, N., M. Lehtonen, K. Varonen, G. A. Goterris, and J. T. Laitinen. 2012. Lipid phosphate phosphatase inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting global LPA degradation. BMC Pharmacol. 12: 7.
340. Nakane, S., S. Oka, S. Arai, K. Waku, Y. Ishima, A. Tokumura, and T. Sugiura. 2002. 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch. Biochem. Biophys. 402: 51-58.
341. Barber, M. N., S. Risis, C. Yang, P. J. Meikle, M. Staples, M. A. Febbraio, and C. R. Bruce. 2012. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE. 7: e41456.
342. Kishimoto, T., Y. Soda, Y. Matsuyama, and K. Mizuno. 2002. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin. Biochem. 35: 411-416.
343. Cho, W. H., T. Park, Y. Y. Park, J. W. Huh, C. M. Lim, Y. Koh, D. K. Song, and S. B. Hong. 2012. Clinical signifi cance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 31: 1805-1810.
344. Sato, K., E. Malchinkhuu, T. Muraki, K. Ishikawa, K. Hayashi, M. Tosaka, A. Mochiduki, K. Inoue, H. Tomura, C. Mogi, et al. 2005. Identifi cation of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fl uid and its possible sources. J. Neurochem. 92: 904-914.
345. Sugiura, T., S. Nakane, S. Kishimoto, K. Waku, Y. Yoshioka, and A. Tokumura. 2002. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J. Lipid Res. 43: 2049-2055.
346. Watanabe, N., H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume, T. Tomiya, K. Tejima, T. Nishikawa, M. Arai, M. Yanase, et al. 2007. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 81: 1009-1015.